@article {FrondaP02.130作者={安娜Fronda安妮Kuan和马文fritzl Kazuo藤和高桥和乔尔·奥格Toshiyuki}, title = {NMO-IgG衡量在多个设施视神经炎(上),横向脊髓炎(TM)及其组合(P02.130)},体积={78}={1}补充数量,页面= {P02.130——P02.130} ={2012},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:比较NMO-IgG抗体结果从不同的实验室(卡尔加里Fritzier博士;首页仙台藤博士;罗切斯特的梅奥诊所)患者和/或TM和评估商业套件AQP4抗体利用ELISA (Kronus)和细胞间接免疫荧光法(IIF Euroimmun)在奥格博士{\ textquoteright}年代温哥华Lab.Background NMO-IgG结合aquaporin-4 (AQP4)和被发现在许多患者视neuromyelitis(动)及其谱系障碍,包括视神经炎(上)和横向脊髓炎(TM)。而异常视觉诱发电位(VEP)表明,存在TM动的特征是长脊髓MRI病灶(s) (LSCMRIL),连续损伤超过三个部分。设计/方法:155例TM和/或在哥伦比亚大学多发性硬化症的临床血清NMO-IgG测试发送至少一个实验室(上面提到的),大多数也化验内部通过ELISA (n = 82)和/或国际(n = 97)。综述了他们的图表和TM的历史,并结果和脊髓磁共振成像。百分比NMO-IgG血清反应阳性的每个设备/分析计算的组合,TM、VEP异常和LSCMRIL。在缺乏临床或TM、亚临床并TM分别定义为异常或LSCMRIL。结果:NMO-IgG血清阳性患者在临床和异常之间的远程33和50 \ %,相比5 - 27 \ %的患者临床TM和LSCMRIL。21岁到38和TM \ %的患者,临床或亚临床,NMO-IgG血清反应阳性的而只有临床或TM 5到13 \ % NMO-IgG试验阳性。结论:NMO-IgG比TM更好的的标志。 Furthermore, there is greater proportion of seropositive patients with both ON and TM, clinical or subclinical, than with ON or TM only. The agreement between the immune techniques/labs was excellent.Disclosure: Dr. Fronda has nothing to disclose. Dr. Kuan has nothing to disclose. Dr. Fritzler has received personal compensation for activities with GlaxoSmithKline, Inc., INOVA Diagnostics, ImmunoConcepts, and Bio Rad. Dr. Fritzler holds stock and/or stock options in AFEXA Life Sciences, which sponsored research in which Dr. Fritzler was involved as an investigator. Dr. Fritzler holds stock and/or stock options in AFEXA Life Sciences. Dr. Fritzler has received research support from University Technologies Inc. Dr. Fujihara has received personal compensation for Bayer Schering Pharma, Biogen Idec, Merck Serono, Biogen Idec, Eisai Inc., Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, and Asahi Kasei Kuraray Medical Co., Ltd. Dr. Fujihara has received personal compensation in an editorial capacity for Clinical and Experimental Neuroimmunology. Dr. Fujihara has received research support from Bayer Schering Pharma, Biogen Idec Japan, Asahi Kasei Kuraray Medical Co., The Chemo-Sero-Therapeutic Research Institute, Teva Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Teijin Pharma, Eisai Inc., and Kyowa Pharmaceuticals America, Inc. Dr. Takahashi has nothing to disclose. Dr. Oger has received personal compensation for activities with Aspreva, Sanofi-Aventis Pharmaceuticals, Inc., Bayer Pharmaceuticals Corporation, Biogen Idec, EMD Serono, Genentech, Inc., Schering, Talecris, and Teva Neuroscience. Dr. Oger has received research support to his University to use Biacore to evaluate neutralizing antibodies to interferon.Tuesday, April 24 2012, 07:30 am-12:00 pm}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/78/1_Supplement/P02.130}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }